Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02178800 · ClinicalTrials.gov registry record · Phase 2
Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults
A Phase 2 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 199
- Enrollment target
- 8
- Study locations
NCT02178800 is a Phase 2 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 199 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (55% lower). The trial reports 8 study locations across 6 states.
The verdict
NCT02178800, a Phase 2 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 199 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study will evaluate the safety, tolerability, and pharmacokinetics (which is how the body interacts with drugs) of an investigational, injectable HIV medicine (GSK1265744) in healthy, HIV-uninfected adults.
Conditions Studied
Interventions
- DRUG GSK1265744 Tablets
- DRUG Injectable GSK1265744
- DRUG Placebo for GSK1265744 Tablets
- DRUG Injectable Placebo for GSK1265744
Study Locations (8)
California
- UCLA CARE Center CRS - Los Angeles
- Bridge HIV CRS - San Francisco
Other
- Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS - Rio de Janeiro
- Malawi CRS - Lilongwe
District of Columbia
- George Washington Univ. CRS - Washington D.C.
North Carolina
- Chapel Hill CRS - Chapel Hill
Gauteng
- Soweto HPTN CRS - Johannesburg
KwaZulu-Natal
- Vulindlela CRS - Durban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 199 participants |
| Start Date | 2015-02 |
| Est. Completion | 2018-07-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02178800
The ClinicalTrials.gov registry entry for NCT02178800 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 199 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (55% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 4 interventions - of which GSK1265744 Tablets is the first listed.
NCT02178800 reports 8 study locations spanning 6 distinct geographic areas - top geographies include California, Other, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT02178800 about?
NCT02178800 is a clinical study titled "Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults". This study will evaluate the safety, tolerability, and pharmacokinetics (which is how the body interacts with drugs) of an investigational, injectable HIV medicine (GSK1265744) in healthy, HIV-uninfected adults.
What is the current status of trial NCT02178800?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 199 participants. The study started on 2015-02. Estimated completion is 2018-07-13.
What conditions does trial NCT02178800 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT02178800?
The interventions under investigation include: GSK1265744 Tablets (DRUG), Injectable GSK1265744 (DRUG), Placebo for GSK1265744 Tablets (DRUG), Injectable Placebo for GSK1265744 (DRUG).
Who is sponsoring clinical trial NCT02178800?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02178800 being conducted?
This trial has 8 study locations across California, District of Columbia, North Carolina, Gauteng, KwaZulu-Natal. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.